newsfilter
← Latest News
ACCESS Newswire·

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

TELO
  • Telomir Pharmaceuticals (NASDAQ: TELO) executed a binding Letter of Intent to acquire TELI Pharmaceuticals, securing worldwide rights to its lead investigational therapy, Telomir-1.
  • The transaction unifies Telomir's U.S. rights with TELI's ex-U.S. intellectual property portfolio across Europe, Canada, China, Japan, and other regions to create a single global owner.
  • Under the agreement, TELI shares will be exchanged for Telomir stock at a ratio determined by independent valuation.
  • The deal includes potential shareholder contributions of up to $5 million in cash or equivalents: $1 million at closing, $2 million upon IND acceptance, $2 million upon Phase 1/2 initiation.
  • Global oncology spending is projected to reach approximately $409 billion by 2028, with ex-U.S. markets accounting for the majority of this spend.
  • Telomir-1 is an oral small-molecule therapy designed to reset DNA methylation, stabilize telomeres, and address root causes of cancer, aging, $amp; degenerative diseases.
  • Preclinical data show Telomir-1 efficacy in triple-negative breast cancer, pancreatic cancer, prostate cancer, age-related macular degeneration, Progeria, Wilson's disease, Type 2 diabetes, $amp; longevity models.
  • CEO Erez Aminov stated the acquisition transforms Telomir-1 into a global platform for partnerships, licensing, $amp; potential asset sales.
  • The transaction is subject to shareholder approval, customary due diligence, regulatory conditions, $amp; includes a six-month lockup for TELI shareholders.